Navigation Links
Decoy makes sitting duck of superbugs
Date:12/4/2007

Scientists from the John Innes Centre have proven that by taking a short stretch of DNA from a bacterium and delivering it with an existing antibiotic they can switch off antibiotic resistance.

Together with technology transfer company PBL, the scientists have launched a spin-out company, Procarta Biosystems Ltd, to develop the technology.

The DNA sequence acts as a decoy, disrupting gene expression and blocking resistance, said Dr Michael McArthur from JIC.

We are putting genetic information directly into drugs. This is the first application of a DNA based therapy.

The scientists have also patented a way of discovering decoys in bacteria without necessarily having to know the genes involved. This means they can develop effective new drugs against any bacterium within a couple of years and at a fraction of the normal cost.

The technology can give fresh patent life to existing antibiotics - when combined with a decoy they can be patented as a new drug.

This comes at a time when the number of new antibiotics receiving approval has dramatically declined. Faced with antibiotic resistance the pharmaceutical industry is unlikely to be able to deliver new products.

Natural resistance will always be hot on the heels of a new antibiotic because they co-evolve, said Dr McArthur. Ours is not a traditional pharmaceutical approach and provides a completely new challenge to bacteria.

The technology can also be used to improve the production of antibiotics by bacteria and to produce enzymes and other compounds using bacteria for use in industrial processes.

Many industrial processes are harsh and unsustainable, using petrochemicals, high temperatures and creating toxic by-products. In industrial biotechnology, also called white biotechnology, bacteria make medically and commercially important compounds biologically.

By using bacteria, many industrial processes could be cleaned up, said Dr McArthur.

The Procarta scientists found that the bacterium Streptomyces produces a particularly high yield of enzymes and proteins. Unusually, it can also secrete the proteins it produces so they do not have to be extracted.

Streptomyces is the enzyme producing bacterium with bells and whistles, set to make a major contribution to a market already predicted to be worth 400 million by 2010, said Dr McArthur.

We use the products of white biotechnology in our everyday lives. They contribute to ingredients in the food we eat, energy we use that has been generated with renewable biomass rather than fossil fuels, medicines we take, and everyday products such as detergents, paint and paper.


'/>"/>

Contact: Zoe Dunford
zoe.dunford@bbsrc.ac.uk
44-160-325-5111
Norwich BioScience Institutes
Source:Eurekalert

Related biology news :

1. New drug makes weight loss safer
2. How mother of thousands makes plantlets
3. For honey bee queens, multiple mating makes a difference
4. Scientists spy enzyme that makes us unique
5. Thinking makes it so: Science extends reach of prosthetic arms
6. Choosing dry or wet food for cats makes little difference
7. Technique controls nanoparticle size, makes large numbers
8. MU study finds that sitting may increase risk of disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology: